Peptide Tools to Study Autoimmune Diseases


About Autoimmune Diseases

  • Abnormal immune responses directed towards the body's own proteins (self-antigens)
  • Leads to tissue damage
  • 80 types of autoimmune diseases known such as systemic lupus erythematosus, celiac disease, diabetes mellitus type 1, Graves' disease, multiple sclerosis and rheumatoid arthritis
  • Causes are mostly unknown, diagnosis can be difficult
  • Treatments can improve symptoms
  • Autoimmune diseases cannot be cured

Target & Epitope Discovery

Target and epitope discovery represent major challenges to enable early diagnosis and the development of suitable treatment strategies. JPT possesses a variety of unique high-throughput peptide-based technologies enabling deep discovery of relevant targets as well as systematic discovery of B- and T-cell epitopes.

In addition, our ultra-fast and cost efficient peptide synthesis strategies together with sophisticated bioinformatics approaches enable sequence diversity considerations (splice variants, mutations etc.) and post-translational modifications that have not previously been addressed from proteome-spanning perspectives.


JPT's peptide tools to study autoimmune diseases  


JPT's Autoimmune Peptide Formats

Discovery

SpotMix Antigen Discovery Pools
SpotMix Antigen Discovery Pools consist of overlapping & pooled peptides synthesized by our proprietary ultra-high throughput SPOT technology. SPOT peptides are synthesized in small amounts fully automated, quickly, at low cost and then pooled to span an entire antigen. SpotMix Pools are optimal for broad antigen target discovery.

Our customized peptide libraries with flexible layout and specifications are optimized for the use in T-cell assays such us ELISpot and intracellular cytokine staining. Applications range from epitope discovery and validation to the development of epitope based cellular therapy concepts.

PepMix™ purified peptide pools spanning entire antigens are highly efficient tools used to validate immune relevant antigens for research, immune monitoring and development of immune therapy concepts. Our custom designed 2D and 3D matrix pools enable antigen spanning T-cell epitope discovery saving time and precious patient samples. The validated pooling strategy ensures the presence of all peptides in a pool with guaranteed purity for each peptide.

Our customized peptide microarrays for profiling of patient samples or antibodies display overlapping peptide scans through antigens or antigen collections. You define content and layout, we provide economic and fast production in our regulated clean-room environment. We also offer a comprehensive assay and analysis service for your samples!

JPT offers pools of proteotypic peptides for the detection and relative quantification of relevant antigens and immunodominant epitopes. The peptide pools incorporate stable isotope labeled peptides for use in mass spectrometry-based MRM assays.

We are the experts for peptide synthesis with highest quality optimized for many applications. Our peptide synthesis service has a very high success rate (over 99%) as we optimize the appropriate peptide synthesis method for each peptide.
If you would like to order a quality peptide synthesis using regulated processes, choose JPT!

Cellular Immune Response

JPT’s immune monitoring tools for cellular immune response target specific antigens or antigen families. JPT’s unique combination of technical and bioinformatics knowledge provides efficient epitope resolved profiling of cellular immune responses that can be correlated to clinical data.

Our widely used PepMixes™ are available in a large variety of off-the-shelf peptide pools or tailored to your specific application and antigen. They contain peptides of defined purity and amount. We also offer a wide variety of standardization and control pools such as CEFX/ EFX Pools and HCMV (pp65).


Humoral Immune Response

Our humoral immune monitoring tools and services for high resolution profiling of target specific antigens or antigen families. A combination of technical and bioinformatics knowledge provides efficient epitope resolved profiling.

PepSpots are membrane bound peptide arrays (PepSpots) for efficient and inexpensive antibody epitope mapping or protein-protein interaction studies. PepSpot is the method of choice for fast and reliable antibody epitope mapping and characterization using purified antibodies.

Our customized peptide microarrays for immune profiling and monitoring display overlapping peptide scans through antigens or selected amino acid sequences. You define content and layout; we provide economical and rapid production in our regulated clean-room environment. We also offer assay and analysis services for your samples with a tailored peptide microarray.

Loading...

References

References

  • Autoantigen-specific CD4+ T cells acquire an exhausted phenotype and persist in human antigenspecific autoimmune diseases
    Saggau et al., Immunity (2024) - PMID: 39226901
    Product used: 
    PepMix™ Human (MOG)
  • Human antibody profling technologies for autoimmune disease
    Carlton et al., Immunologic Research (2023)
    Product used: Custom PepStar Peptide Microarrays & PepSpots Peptides on Cellulose
  • Expression of Programmed Death Ligand (PD-L1) in Different Tumors. Comparison of Several Current Available Antibody Clones and Antibody Profiling
    Kintsler et al., Annals of Diagnostic Pathology (2019)
  • First-Trimester Proteomic Profiling Identifies Novel Predictors of Gestational Diabetes Mellitus
    Ravnsborg et al, PLoS One (2019)
  • Trapped in the Epineurium: Early Entry Into the Endoneurium is Restricted to Neuritogenic T Cells in Experimental Autoimmune Neuritis
    Mausberg et al, Journal of Neuroinflammation (2018)


Testimonial

Testimonial

"The focus of the Clinical Immunology Group at the German Rheumatism Research Centre is to study the role of cells and molecules in the origin and progression of autoimmune and other diseases. In our hands PepMixes™ were found to be effective in monitoring the immune status of various patient populations but show also promise for the development of novel immuno therapy approaches."
Dr. Andreas Thiel (German Rheumatism Research Centre, Clinical Immunology, Berlin, Germany)

Application Note
Loading...

Check our list of products, click and go.

Get a quote